Aquestive Therapeutics Inc
AQST3.926USD
+0.106+2.77%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
389.92MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Aquestive Therapeutics Inc Unternehmen
Aquestive Therapeutics, Inc. is a pharmaceutical company. The Company is developing pharmaceutical products to deliver complex molecules through administrations that are alternatives to invasive and inconvenient standard of care therapies. It is advancing a product pipeline for the treatment of severe allergic reactions, including anaphylaxis. It has also developed a product pipeline focused on treating diseases of the central nervous system (CNS). Its PharmFilm technology is comprised of proprietary polymer compositions that serve as film formers to hold active pharmaceutical ingredients (APIs), and excipients in place. Its product portfolio and pipeline include Anaphylm, AQST-108, and Adrenaverse. Its CNS product candidate include Libervant. The Company’s Licensed commercial products and product candidates and other product includes Suboxone, Exservan, KYNMOBI, Zuplenz, Azstarys, Libervant, and Sympazan. Anaphylm is a non-device based, orally delivered epinephrine product candidate.
Unternehmensinformationen
BörsenkürzelAQST
Name des UnternehmensAquestive Therapeutics Inc
IPO-datumJul 25, 2018
CEOMr. Daniel Barber
Anzahl der mitarbeiter142
WertpapierartOrdinary Share
GeschäftsjahresendeJul 25
Addresse30 Technology Dr
StadtWARREN
BörseNASDAQ Global Market Consolidated
LandUnited States of America
Postleitzahl07059-5166
Telefon19089411900
Websitehttps://aquestive.com/
BörsenkürzelAQST
IPO-datumJul 25, 2018
CEOMr. Daniel Barber
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Daniel Barber
Mr. Daniel Barber
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.85M
+33.44%
Ms. Lori J. Braender, J.D.
Ms. Lori J. Braender, J.D.
Chief Legal Officer, Chief Compliance Officer and Corporate Secretary
Chief Legal Officer, Chief Compliance Officer and Corporate Secretary
649.24K
+36.11%
Dr. Carl N. Kraus, M.D.
Dr. Carl N. Kraus, M.D.
Chief Medical Officer
Chief Medical Officer
313.57K
+24.59%
Mr. Peter E. Boyd
Mr. Peter E. Boyd
Senior Vice President - Information Technology, Human Resources and Communications
Senior Vice President - Information Technology, Human Resources and Communications
303.11K
+27.67%
Ms. Cassie Jung
Ms. Cassie Jung
Chief Operating Officer
Chief Operating Officer
293.84K
+26.99%
Ms. Sherry Korczynski
Ms. Sherry Korczynski
Chief Commercial Officer
Chief Commercial Officer
156.86K
-1.70%
Dr. Gregory B. Brown, M.D.
Dr. Gregory B. Brown, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
75.08K
--
Dr. Marco Taglietti, M.D.
Dr. Marco Taglietti, M.D.
Independent Director
Independent Director
--
--
Mr. Timothy E. Morris, CPA
Mr. Timothy E. Morris, CPA
Independent Director
Independent Director
--
--
Ms. Stephanie Carrington
Ms. Stephanie Carrington
Investor Relations
Investor Relations
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Daniel Barber
Mr. Daniel Barber
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.85M
+33.44%
Ms. Lori J. Braender, J.D.
Ms. Lori J. Braender, J.D.
Chief Legal Officer, Chief Compliance Officer and Corporate Secretary
Chief Legal Officer, Chief Compliance Officer and Corporate Secretary
649.24K
+36.11%
Dr. Carl N. Kraus, M.D.
Dr. Carl N. Kraus, M.D.
Chief Medical Officer
Chief Medical Officer
313.57K
+24.59%
Mr. Peter E. Boyd
Mr. Peter E. Boyd
Senior Vice President - Information Technology, Human Resources and Communications
Senior Vice President - Information Technology, Human Resources and Communications
303.11K
+27.67%
Ms. Cassie Jung
Ms. Cassie Jung
Chief Operating Officer
Chief Operating Officer
293.84K
+26.99%
Ms. Sherry Korczynski
Ms. Sherry Korczynski
Chief Commercial Officer
Chief Commercial Officer
156.86K
-1.70%
Umsatzaufteilung
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
Keine Daten
Nach RegionUSD
Name
Umsatz
Anteil
United States
5.20M
0.00%
Ex-United States
3.52M
0.00%
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Fri, May 23
Aktualisiert: Fri, May 23
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Crestline Investors, Inc.
9.88%
BlackRock Institutional Trust Company, N.A.
5.48%
The Vanguard Group, Inc.
4.10%
Perceptive Advisors LLC
3.75%
Armistice Capital LLC
2.77%
Other
74.02%
Aktionäre
Aktionäre
Anteil
Crestline Investors, Inc.
9.88%
BlackRock Institutional Trust Company, N.A.
5.48%
The Vanguard Group, Inc.
4.10%
Perceptive Advisors LLC
3.75%
Armistice Capital LLC
2.77%
Other
74.02%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
16.61%
Hedge Fund
16.46%
Individual Investor
6.00%
Investment Advisor/Hedge Fund
5.80%
Private Equity
5.10%
Research Firm
4.75%
Bank and Trust
0.10%
Venture Capital
0.08%
Pension Fund
0.02%
Other
45.09%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
267
54.56M
54.93%
-2.83M
2025Q1
270
54.42M
54.80%
-3.81M
2024Q4
246
52.68M
57.78%
-5.60M
2024Q3
235
56.04M
61.46%
+1.93M
2024Q2
197
48.34M
53.08%
-1.69M
2024Q1
166
46.95M
51.85%
+18.59M
2023Q4
129
27.01M
40.12%
+751.99K
2023Q3
131
26.75M
41.08%
+3.52M
2023Q2
143
22.79M
40.65%
+3.05M
2023Q1
161
18.71M
33.39%
-2.52M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Crestline Investors, Inc.
9.81M
9.88%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
5.44M
5.48%
-78.94K
-1.43%
Mar 31, 2025
The Vanguard Group, Inc.
4.07M
4.1%
-273.20K
-6.29%
Mar 31, 2025
Perceptive Advisors LLC
3.73M
3.75%
+3.73M
--
Mar 31, 2025
Armistice Capital LLC
2.75M
2.77%
+2.75M
--
Sep 30, 2024
Barber (Daniel)
1.85M
1.86%
+462.91K
+33.44%
Mar 21, 2025
Geode Capital Management, L.L.C.
1.70M
1.71%
+46.11K
+2.79%
Mar 31, 2025
State Street Global Advisors (US)
1.52M
1.53%
+18.76K
+1.25%
Mar 31, 2025
Pale Fire Capital SE
1.34M
1.34%
+809.93K
+154.05%
Mar 31, 2025
BofA Global Research (US)
1.33M
1.34%
+640.24K
+92.75%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
Invesco NASDAQ Future Gen 200 ETF
0.55%
iShares Micro-Cap ETF
0.06%
Invesco Nasdaq Biotechnology ETF
0.04%
ProShares Ultra Nasdaq Biotechnology
0.04%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.03%
ProShares Hedge Replication ETF
0.01%
iShares Russell 2000 Value ETF
0.01%
ProShares UltraPro Russell2000
0.01%
Proshares Ultra Russell 2000
0.01%
Global X Russell 2000 ETF
0.01%
Mehr Anzeigen
Invesco NASDAQ Future Gen 200 ETF
Anteil0.55%
iShares Micro-Cap ETF
Anteil0.06%
Invesco Nasdaq Biotechnology ETF
Anteil0.04%
ProShares Ultra Nasdaq Biotechnology
Anteil0.04%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Anteil0.03%
ProShares Hedge Replication ETF
Anteil0.01%
iShares Russell 2000 Value ETF
Anteil0.01%
ProShares UltraPro Russell2000
Anteil0.01%
Proshares Ultra Russell 2000
Anteil0.01%
Global X Russell 2000 ETF
Anteil0.01%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
